TNFRSF8 and lymphoma: For example, combining the tetravalent bispecific engager AFM13 which targets CD30 on lymphoma cells and CD16 on NK cells, with pre-activated cord blood-derived NK cells demonstrated improved control of CD30+ lymphoma in vivo compared to AFM13 or pre-activated NK cells alone [99].